ES2091000T3 - Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas. - Google Patents

Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas.

Info

Publication number
ES2091000T3
ES2091000T3 ES93911369T ES93911369T ES2091000T3 ES 2091000 T3 ES2091000 T3 ES 2091000T3 ES 93911369 T ES93911369 T ES 93911369T ES 93911369 T ES93911369 T ES 93911369T ES 2091000 T3 ES2091000 T3 ES 2091000T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
synthesis
arylalkyl
retroviric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911369T
Other languages
English (en)
Inventor
John S Ng
Claire A Przybyla
Richard A Mueller
Michael L Vazquez
Daniel P Getman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
GD Searle LLC
Original Assignee
Monsanto Co
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co, GD Searle LLC filed Critical Monsanto Co
Application granted granted Critical
Publication of ES2091000T3 publication Critical patent/ES2091000T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/22—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UNA SINTESIS PARA INTERMEDIOS QUE SON FACILMENTE SUSCEPTIBLES DE PREPARACION A GRAN ESCALA DE INHIBIDORES DE PROTEASA VIH QUIRAL BASADOS EN HIDROXIETILUREA. EL METODO COMPRENDE LA FORMACION DE UN COMPUESTO EPOXIDO DIAESTEREOSELECTIVO DE FORMULA (I) DE UN ALDEHIDO ALFAAMINO QUIRAL Y HALOMETILITIO COMO REACTIVO DE ADICION DE METILENO. EN LA FORMULA (I) (R1) SE ELIGE ENTRE ALQUILO, ARILO, CICLOALQUILO, CICLOALQUILALQUILO, Y ARILALQULILO, QUE SE SUSTITUYEN OPCIONALMENTE CON UN GRUPO ELEGIDO A PARTIR DE ALQUILO, HALOGENO, NO2, OR9 O SR9, DONDE R9 REPRESENTA HIDROGENO O ALQUILO; Y P1 Y P2 INDEPENDIENTEMENTE SE ELIGEN ENTRE GRUPOS PROTECTORES A MINA, QUE COMPRENDEN PERO NO SE LIMITAN A ARILALQUILO, ARILALQUILO, CICLOALENILALQUILO Y CICLOALQUENILALQUILO, ALILO, ALILO SUSTITUIDO, ACILO, ALCOSICARBONILO, ARALCOXICARBONILO Y SILILO.
ES93911369T 1992-05-20 1993-05-20 Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas. Expired - Lifetime ES2091000T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88655892A 1992-05-20 1992-05-20

Publications (1)

Publication Number Publication Date
ES2091000T3 true ES2091000T3 (es) 1996-10-16

Family

ID=25389250

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911369T Expired - Lifetime ES2091000T3 (es) 1992-05-20 1993-05-20 Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas.

Country Status (11)

Country Link
EP (1) EP0641333B1 (es)
JP (3) JP3492362B2 (es)
KR (1) KR100290516B1 (es)
AT (1) ATE141265T1 (es)
AU (2) AU4253193A (es)
CA (1) CA2131182C (es)
DE (1) DE69304051T2 (es)
DK (1) DK0641333T3 (es)
ES (1) ES2091000T3 (es)
GR (1) GR3020814T3 (es)
WO (2) WO1993023388A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
JP4117901B2 (ja) * 1993-05-21 2008-07-16 アメリカ合衆国 デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法
AU7518694A (en) * 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
CN1146201A (zh) * 1994-03-07 1997-03-26 沃泰克斯药物股份有限公司 用作天冬氨酰蛋白酶抑制剂的磺胺衍生物
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
CA2137406C (en) * 1994-12-06 2005-09-13 Pierre Louis Beaulieu Process for key intermediates for hiv protease inhibitors
US5481011A (en) * 1994-12-13 1996-01-02 Bristol-Myers Squibb Company Process for preparing N-protected amino acid α-halomethyl ketones and alcohols from N-protected amino acid esters
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
ATE382041T1 (de) 1995-01-20 2008-01-15 Searle Llc Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5693847A (en) * 1995-04-19 1997-12-02 Vertex Pharmaceuticals Incorporated Heteroatom functionalized α-methyl ketones
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6063963A (en) * 1995-07-05 2000-05-16 Pharm-Eco Laboratories, Inc. Amino acid-derived diaminopropanols
DK0861233T3 (da) 1995-11-16 2000-08-07 Searle & Co N-Beskyttede/N-substituerede beta-aminohydroxysulfonater
US5767316A (en) * 1995-11-17 1998-06-16 Ajinomoto Co., Inc. Process for producing 3-amino-2-oxo-1-halogenopropane derivatives
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5919956A (en) * 1996-10-18 1999-07-06 Roche Vitamins Inc. Process for the C1 -homologization of protected phorenol
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6127556A (en) * 1996-12-31 2000-10-03 G. D. Searle & Co. Epoxide formation by continuous in-situ synthesis process
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EP1086076B1 (en) 1998-06-19 2004-12-22 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
DE60038899D1 (de) 2000-01-19 2008-06-26 Abbott Lab Hiv-proteasehemmern
FR2820136A1 (fr) * 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
ATE450262T1 (de) 2005-11-25 2009-12-15 Galapagos Sas Harnstoff-derivate als calcium-rezeptor- modulatoren
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297631C (en) * 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CH676988A5 (es) * 1987-01-21 1991-03-28 Sandoz Ag
USH725H (en) * 1987-02-26 1990-01-02 E. R. Squibb & Sons, Inc. Ureido amino and imino acids, compositions and methods for use
DE3711911A1 (de) * 1987-04-08 1988-10-20 Bayer Ag Optisch aktive (alpha)-aminoaldehyde, verfahren zu ihrer herstellung und ihre verwendung zur stereoselektiven herstellung optisch aktiver ss-aminoalkohole
EP0374097A3 (de) * 1988-12-15 1991-06-12 Ciba-Geigy Ag Verwendung von Peptidisosteren als retrovirale Proteasehemmer
ATE296626T1 (de) * 1990-11-19 2005-06-15 Monsanto Co Retrovirusprotease inhibitoren

Also Published As

Publication number Publication date
KR100290516B1 (ko) 2001-09-17
JP2003192648A (ja) 2003-07-09
JP2003160545A (ja) 2003-06-03
CA2131182A1 (en) 1993-11-25
WO1993023388A1 (en) 1993-11-25
AU676479B2 (en) 1997-03-13
WO1993023368A1 (en) 1993-11-25
DK0641333T3 (da) 1996-09-02
AU4253193A (en) 1993-12-13
ATE141265T1 (de) 1996-08-15
GR3020814T3 (en) 1996-11-30
AU4253093A (en) 1993-12-13
EP0641333B1 (en) 1996-08-14
KR950700893A (ko) 1995-02-20
JP3492362B2 (ja) 2004-02-03
EP0641333A1 (en) 1995-03-08
DE69304051T2 (de) 1997-01-23
JPH07508041A (ja) 1995-09-07
DE69304051D1 (de) 1996-09-19
CA2131182C (en) 2005-04-26

Similar Documents

Publication Publication Date Title
ES2091000T3 (es) Metodo para elaborar intermedios utiles en la sintesis de inhibidores de proteasas retroviricas.
KR850001171A (ko) 퀴놀린 화합물의 제조방법
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
KR860001793A (ko) 벤즈 이미다졸 유도체의 제조방법
HUP0000734A2 (hu) Antivirális hatású keton-származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás a gyógyszerkészítmények előállítására
HUP9902576A1 (hu) Új eritromicinszármazékok, eljárás előállításukra és alkalmazásuk gyógyászati készítményekben
KR840001949A (ko) 신규 펩티드 화합물의 제법
ATE26263T1 (de) 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepine, verfahren zur herstellung derselben und ihre verwendung als heilmittel.
KR850006194A (ko) 치환된 벤조피란의 제조방법
DE69524578T2 (de) Verfahren zur herstellung von epoxiden
EP0245902A3 (en) Benzothiazinone derivatives
ATE372332T1 (de) Verfahren zur herstellung von zwischenverbindungen in der herstellung von discodermolid und discodermolid-analoga
WO1998051672A3 (en) A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives
ATE380173T1 (de) Verfahren zur herstellung von (2s,3r,4s)-4- hydroxyisoleucin und analoga
ATE244224T1 (de) Verfahren zur umwandlung von 2,4-dichlorpyridinen in 2-aryloxy-4-chlorpyridine
ATE271551T1 (de) Verfahren zur herstellung von n-(1-(s)- ethoxycarbonyl-3-phenylpropyl)-l-alanin-n- carboxyanhydrid
BR0008936A (pt) Derivados de 1,3,4-oxadiazol e processo para produzir os mesmos
HUP0105111A1 (hu) 2,5-Helyettesített benzolszulfonilkarbamid- és tiokarbamidszármazékok, eljárás előállításukra, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
DE69839732D1 (de) Verfahren zur herstellung von 3,4-dihydroxy-3cyclobuten-1,2-dion
DK70184A (da) Fremgangsmaade til fremstilling af chromenderivater
HUP0203214A2 (hu) Eljárás HIV-proteáz gátló szintézisénél alkalmazható intermedierek előállítására
HUP9800372A2 (hu) Eljárás transz fenil-glicidilsav-származékok előállítására
DE69616801D1 (de) Eintopfverfahren zur herstellung von 2-oxazolidinonderivate
DK151332C (da) Analogifremgangsmaade til fremstilling af dibenzoxazonin-, dibenzoxazecin- eller dibenzoxaazacykloundecanderivater eller de tilsvarende thia- eller azaderivater eller farmaceutisk acceptable syreadditionssalte deraf
ATE42299T1 (de) Verfahren zur herstellung von n(dibenzyloxyphosphoryl)-cyanamid und die verfahren, die solche verbindungen als zwischenprodukt fuer die synthese von phosphagenstoffen verwenden.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641333

Country of ref document: ES

FG2A Definitive protection

Ref document number: 641333

Country of ref document: ES